Topical DHEA Against Vaginal Atrophy
Topical DHEA Against Vaginal Atrophy
The purpose of this study is to determine the dose-response of vaginal mucosa parameters to
 the local action of DHEA (Dehydroepiandrosterone) in postmenopausal women suffering from
 vaginal atrophy.
Inclusion Criteria:

 -  Postmenopausal women (non hysterectomized or hysterectomized)

 -  Women between 40 and 75 years of age

 -  Willing to participate in the study and sign an informed consent

 -  Women having a low maturation index (no greater part of guidance than 5% of
 superficial cells on vaginal smear)

 -  Women having a vaginal pH above 5

 -  Women who have self-identified at least one moderate to severe symptoms of
 vulvovaginal atrophy

 Exclusion Criteria:

 -  Undiagnosed abnormal genital bleeding

 -  Hypertension equal to or above 160/95 mm Hg or not controlled by standard therapy

 -  The administration of any investigational drug within 30 days of screening visit

 -  Endometrial hyperplasia at biopsy performed at screening or endometrial cancer

 -  Use of estrogens/progestins products (vaginal, oral, pellet, transdermal, etc) in the
 4 weeks to 6 months (depending on the product used) prior study entry